Simplex Trading’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-243,200
| Closed | -$982K | – | 8746 |
|
|
2025
Q1 | $982K | Sell |
243,200
-48,300
| -17% | -$161K | ﹤0.01% | 2722 |
|
|
2024
Q4 | $932K | Buy |
291,500
+160,100
| +122% | +$543K | ﹤0.01% | 2912 |
|
|
2024
Q3 | $294K | Sell |
131,400
-16,000
| -11% | -$36.9K | ﹤0.01% | 4153 |
|
|
2024
Q2 | $316K | Buy |
147,400
+46,300
| +46% | +$82.4K | ﹤0.01% | 4163 |
|
|
2024
Q1 | $207K | Buy |
101,100
+92,800
| +1,118% | +$185K | ﹤0.01% | 4812 |
|
|
2023
Q4 | $19K | Sell |
8,300
-5,100
| -38% | -$11.1K | ﹤0.01% | 6958 |
|
|
2023
Q3 | $22K | Sell |
13,400
-17,300
| -56% | -$39.3K | ﹤0.01% | 6531 |
|
|
2023
Q2 | $75K | Buy |
30,700
+2,600
| +9% | +$7.1K | ﹤0.01% | 5404 |
|
|
2023
Q1 | $63K | Buy |
28,100
+5,200
| +23% | +$26.1K | ﹤0.01% | 5653 |
|
|
2022
Q4 | $117K | Buy |
22,900
+19,080
| +499% | +$137K | ﹤0.01% | 4878 |
|
|
2022
Q3 | $39K | Sell |
3,820
-3,680
| -49% | -$43.8K | ﹤0.01% | 6759 |
|
|
2022
Q2 | $77K | Sell |
7,500
-930
| -11% | -$12.2K | ﹤0.01% | 5926 |
|
|
2022
Q1 | $149K | Buy |
8,430
+6,690
| +384% | +$144K | ﹤0.01% | 5588 |
|
|
2021
Q4 | $54K | Buy |
1,740
+1,250
| +255% | +$41.4K | ﹤0.01% | 7155 |
|
|
2021
Q3 | $14K | Buy |
490
+100
| +26% | +$2.96K | ﹤0.01% | 8711 |
|
|
2021
Q2 | $11K | Buy |
390
+389
| +38,900% | +$10.8K | ﹤0.01% | 9022 |
|
|
2021
Q1 | $4K | Buy |
+1
| New | +$34 | ﹤0.01% | 8252 |
|
Simplex Trading's CKPT Position: Q1 2024 in Review
Simplex Trading sold out of Checkpoint Therapeutics (CKPT) in Q1 2024, closing a stake of 13,611 shares — an estimated $27.2K sold.
Simplex Trading first reported a position in CKPT in Q1 2021 and held it in 9 quarters. The position peaked at $334K in Q4 2021. 40 funds tracked by Wall St. Rank hold CKPT as of Q1 2024.
- Simplex Trading reported no remaining Checkpoint Therapeutics position as of Q1 2024 after selling out during the quarter.
- Simplex Trading sold 13,611 Checkpoint Therapeutics shares in Q1 2024, an estimated $27.2K.
- Simplex Trading first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 9 quarters.
- Simplex Trading's Checkpoint Therapeutics position peaked at $334K in Q4 2021.
- 40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2024.
Based on Simplex Trading's 13F filing for Q1 2024, filed 25 Apr 2024.